SCIMITAR is the first phase 2 trial testing the efficacy of stereotactic body radiation therapy (SBRT) targeting the prostate fossa after radical prostatectomy.

Multiparametric MRI detects more local recurrences after prostatectomy than prostate-specific membrane antigen PET-CT, with the two showing only moderate agreement.

Patients who developed biochemical recurrence had a higher PSA at diagnosis, more advanced pT stages, a higher rate of pN1 stage disease, a higher rate of R1 or Rx resection, and a higher rate of ...

Patients who reported current multivitamin use had a lower risk of recurrence than patients who had never taken multivitamins. Patients with prostate cancer may have a lower risk of recurrence if they ...

The precise identification of tumor boundaries during radical prostatectomy remains a major clinical challenge. As positive ...

While prostate cancer recurrence is a major cause of death in patients receiving localized treatment, there are other significant causes of mortality. While prostate cancer progression or recurrence ...

XTANDI: the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical ...

A groundbreaking new study has found that a combination of two drugs can boost survival rates in prostate cancer patients by up to 40 per cent. The treatment pairs standard hormone therapy with a ...

After skin cancer, prostate cancer is the most common cancer among men in the U.S., and 20% to 30% of men who beat it once will face a recurrence within five years. A new treatment, known as salvage ...

CLEVELAND, Ohio (Ivanhoe Newswire) - After skin cancer, prostate cancer is the most common cancer in men in the US. For the men who have beat prostate cancer once, 20 to 30 percent will show signs of ...